Episode 306: 305. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline
https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae290/7685305?login=trueChildren aged 1-18 years to prevent rickets and to potentially lower the risk for respiratory tract infection...
21 Jun 202414min
Episode 305: 304. METHODS MONDAY- What is Power?
What is the power of a study—what is the power calculation? Often say it is the number of people in a study. Power is the probably to correctly reject the null hypothesis. Said differently power is th...
17 Jun 202415min
Episode 304: 303. Associations Between Surrogate Markers and Clinical Outcomes
Question What is the strength of association between surrogate markers used as primary end points in clinical trials to support Food and Drug Administration (FDA) approval of drugs treating nononcolo...
14 Jun 20245min
Episode 303: 302. Effects of statin therapy on diagnoses of new-onset diabetes
The incidence of new-onset diabetes was basically the same but statistically significantly higher for those individuals on low-to-moderate–intensity statins compared with placebo 1.2 vs 1.3% annually ...
13 Jun 20246min
Episode 302: 301. Development and Validation of the American Heart Association's PREVENT Equations
At change in c stats of 0.007 or 0.0009 is not a meaningful change so I cant say we should use this over the PCE—yes this new calculator has the benefit of removal of race, and the use race-based algo...
12 Jun 202411min
Episode 301: 300. A New Trial On Beta Blockers and COPD
The problems with observation data is real— randomized trial, U.K. researchers identified 519 patients (mean age, 68) with mostly moderate COPD (mean forced expiratory volume in 1 second [FEV1], 50%)...
11 Jun 20246min
Episode 300: 299. When Do You Use a Cluster RCT?
When you want to do an RCT but you realize there might be some cross contamination so instead of randomizing individuals you randomize cluters or groups Lets say you want to do fluids--- what is bette...
7 Jun 202414min
Episode 299: 298. Do We Have a Reversal Drug for DOACs? ANNEXA or Andexanet
1° outcome: hemostatic efficacy = which was defined as;(A) Hematoma expansion ≤ 35% at 12h(B) increase in NIHSS ≤ 7 at 12h(C) No rescue therapy 3-12h Results hemostatic efficacy: 76.7% andexanet vs...
6 Jun 20249min
